GC

It was newly established by GCJBP, a pharmaceutical company specializing in placental medication,
by acquiring and merging with Green Cross HS, a company specializing in natural medicines and materials,
and GC Biopharma's WB division. In order to become a leader in personalized healthcare solutions
as a companion for a healthy life in an era of 100-year lives, GC Wellbeing supplies a variety of personalized nutritional injections and health functional foods. It also focuses on the research and development of pharmaceuticals and health functional foods derived from natural products.

Through the "Personalized Health Portal" centered on data and mobile experience, GC Care is actively promoting its IT platform business.
Its goal is to enable anyone to easily receive a checkup anytime, anywhere, quickly self-check symptoms and diseases, and enable convenient self-care in daily life.
In addition, GC Care is expanding the provision of "total healthcare service" that links employees’ checkup results with customized daily care services, and is also expanding the role of "smart care coordinator" for chronic patients who require daily health care.

UBcare launched "ysarang", the first Electronic Medical Record (EMR) system in Korea.
Based on its unrivaled market position (25,000 hospitals and clinics /pharmacies and 38 corporate agencies nationwide), UBcare operates businesses such as EMR, distribution, pharmaceuticals/data, and builds high barriers to entry into the medical data industry.
UBcare is focused on securing leadership in the medical big data industry by creating the value of new health data through standardization and convergence of medical data.

Able Analytics provides analysis model development and consulting services such as derivation of data analysis tasks and strategy establishment, customer segmentation, customer profile analysis, customer behavior prediction, product/service recommendation, campaign targeting, demand forecasting, abnormal transaction pattern analysis, to companies in various industries in Korea, and has know-how on data analysis technology that can create practical business value through this.
In particular, Able Analytics is developing a digital healthcare solution tailored to individuals (patients) using technology research on big data utilization and analysis platforms specialized in the healthcare field and the latest AI & machine learning technology.

Starting with blood type diagnostic reagents in 1972, GCMS developed the first AIDS diagnostic reagent in Korea in 1987, followed by epidemic hemorrhagic fever diagnostic reagents in 1990,
achieving great results. Currently, GCMS is striving to improve people's quality of life with accurate diagnosis using its own immunodiagnosis and molecular diagnostic technology,
and is developing further into a global diagnostic medical device company through research and development of various medical devices and home healthcare products.

GC Medis was founded in 2005 under the motto “Bio-IT technology for human, we find the answers from a drop of blood”.
It specializes in point-of-care testing (POCT) based on IT and BIO convergence technology in the field of mobile healthcare and in vitro diagnostics.
GC Medis develops a multi-measurement system for POCT that combines accurate and high-quality blood glucose measurement system products with glycated hemoglobin, inflammatory markers, kidney disease, and blood coagulation markers for POCT, and further expands into the POCT business for companion animals.

GC Genome provides essential clinical genome testing services in the medical field for cancer, rare genetic diseases, prenatal, neonatal, health checkup, and microbiome.
As a leading company in the field of clinical genome analysis in Korea, GC Genome will widen the gap with other companies and grow into a global company recognized overseas.

GCCL is a company specializing in the clinical trial sample analysis and provides analytical services for all phases of clinical trials from phase 1 to phase 4 clinical trials.
GCCL has a platform optimized for clinical trials based on the global quality standards of GCLP qualification, and provides clinical trial sample analysis services to meet customer needs based on its own sample transportation logistics system as well as various analysis experiences. GCCL aims to achieve the grand goal of growing into a trusted company that supports the success of clinical trials for partners in the Asian region and around the world as well as in Korea.

To provide consulting services in the field of veterinary clinical diagnosis and treatment based on reference laboratories, Green Vet's main businesses include diagnostic image consulting service (GV Teleradiology Partners), web clinical consulting service(GV Consultation Network), health checkup and healthcare service (GV Care & Solution Center), etc. Green Vet strives hard to achieve the ideology of One Health by protecting the health of people and the environment and forming a healthy society in order to strengthen the bond between humans and animals. Green Vet's competitiveness is to pursue total healthcare with the entire lifespan of companion animals rather than care limited to a specific field, present a new standard for companion animal business, and strengthen research and development and business capabilities through steady investment. Green Vet aims to enter the global market in the future.

Genes Laboratories covers a full production line from raw materials to finished products (with GMP facilities) based on R&D capabilities, and possesses the industry's best enzyme production and optimization technology.
Genes Laboratories has secured the best capabilities in quality control and cost competitiveness through its own development and production, and systematically supplies raw materials and semi-finished products to many other diagnostic companies.
Genes Laboratories is concentrating all its capabilities to become a world-class company that diagnoses and prevents various diseases of humans and pets by further advancing the technology accumulated over 10 years.

GC LabTech has been established with a global strategy for blood product development, and performs plasma screening tests.
GC LabTech is expanding its business scope from general to special tests, and has obtained international certifications such as CLIA,CAP, and ISO.

GC Biopharma USA is fulfilling its vision of global healthcare by supplying the superior pharmaceutical products proven through GC Biopharma to the United States.

As a Seattle-based company, Curevo is currently conducting clinical trials on its next-generation shingles vaccine (CRV101).
Curevo will continue its global clinical development of innovative prophylactic and therapeutic vaccines against infectious diseases to become a next-generation vaccine specialist.
Through collaboration with the world-renowned vaccine organization IDRI (Infectious Disease Research Institute), Curevo is accumulating expertise in vaccine research.

As a subsidiary of GC Cell, it is a representative cell therapy product research and sales company in Japan.
Since obtaining a "permission to manufacture specific cell processing materials" from Japan’s Ministry of Health, Labor and Welfare in 2015, GC Lymphotech has been producing cell therapy products and providing the related services.

It has been established as a strategy to expand GC Biopharma' business into South America.
GC biopharma do Brasil contributes to the growth of sales in South America by providing local services necessary for products and merchandise businesses such as blood products, vaccines, and orphan drugs.

Artiva is a "NRDO" (No Research Development Only) company
that introduces GC Cell’s CAR technology and NK cell therapy product pipeline without developing its own original technology.

BioCentriq has specialized capabilities in the development and manufacturing of cell and gene therapy product processes. Based on sufficient manpower, facilities and equipment for the CDMO business at cGMP production facilities located in New Jersey, USA, BioCentriq has been commissioned to develop and produce autologous and allogeneic cell therapy products, gene therapy products, and viral vectors.

This research institute was established in 1984 with the proceeds from the hepatitis B vaccine, which was developed by GC Biopharma, the third in the world.
The Institute was established to create a stable and sustainable research environment through social contribution and profit generated from the development of life science technology and reinvesting the profits into research and development. It is a non-profit research foundation approved by the Ministry of Science and Technology (currently the Ministry of Science and ICT) as the first private research institute in Korea.
Its main research areas are cancer, vaccines, rare diseases and metabolic diseases.

The Mogam Science Scholarship Foundation is a public foundation established in 2005 with a strong will to advance science and technology. It helps young scientists who will lead Korea's science and technology to reach out to the world, and contribute to the development of Korea. For this purpose, the foundation discovers and provides scholarships and research funds to science students who will become the main driving force behind the development of science and technology in Korea.

As a public interest foundation established in 2009, the Future Foundation of Korea operates scholarship programs to help North Korean refugee students grow into leaders in the era of unification with a passion for learning and hope for the future. Recipients of the Scholarship will grow into members of a sharing community that ensures equal rights and bright future. Through this, the foundation helps North Korean refugees settle down in South Korea in terms of living, health, study, job, and norms, and is working together to create a happy future as a good citizen in Korean society.

GC Labs is a medical corporation that started in 1982 as a medical institution specializing in clinical trials, and has strategic partnerships with the world's leading clinical trial institutions. It focuses on open innovation and differentiation, such as the introduction of advanced equipment for special tests centered on university hospitals and the cultivation of excellent R&D personnel. GC Labs safely conducts all tests in the state-of-the-art clinical trial center with a total floor area of ​​3,700 pyeong, designed as a dedicated building for clinical tests for the first time in Korea. In 2008, GC Labs obtained the certifications of ISO9001 for the quality management system and, at the same time,ISO14001 for the environmental management system for the first time as an entrusted institution. The laboratories of GC Labs use state-of-the-art automated systems to perform fast and accurate tests for about 5,000 items 24 hours and 365 days a year, recording the largest number of special tests performed in Korea.

GC I-MED was established in 1991 with a mission to realize Healthpia, an ideal society where everyone is healthy, and serves as a comprehensive medical examination center and a functional medicine treatment center. By grafting a state-of-the-art medical IT system onto a screening care program for efficient health management, GC I-MED provides customized health checkup services from cradle to grave so that all customers can lead a healthy life, thereby preventing disease and providing lifelong health management services. GC I-MED's screening system using state-of-the-art medical equipment and professional medical staff with abundant know-how provide a variety of medical services. GC I-MED is innovating into a health screening center that presents the best solutions for the healthy life of our customers, from the treatment system through linkage with excellent partner hospitals to the U-Healthcare program for post-health care.

Since its establishment in 2001, GCEM has been the only bioengineering & construction company in Korea. Excellent pharmaceutical manufacturing facilities and research laboratories are essential infrastructure for public health. However, no one else has attempted to build these facilities. But GCEM has steadily paved the way to dedicate itself to public health. GCEM is a customer-centered company that creates customer value through the best quality, safe construction, and thorough follow-up management from design to construction, verification, and maintenance with its best technology and services. Not satisfied with this, GCEM will create values ​​that exceed the needs of customers in all fields of bioengineering through business diversification with the goal of becoming a "leader in the bio and GMP construction field".

GC Invacfarm has established the nation's best isolation and quarantine system, operates a poultry farm that produces fertilized eggs under strict quality control standards, and has a hatchery that hatches fertilized eggs to a level suitable for vaccine production. It contributes to the growth and development of GC Biopharma flu vaccine by ensuring a stable supply of high-quality fertilized eggs for the vaccine.